Wall Street brokerages predict that Evogene Ltd. (NASDAQ:EVGN) will post ($0.18) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Evogene’s earnings. Evogene reported earnings of ($0.26) per share in the same quarter last year, which would indicate a positive year over year growth rate of 30.8%. The company is expected to announce its next earnings results on Monday, February 26th.
According to Zacks, analysts expect that Evogene will report full year earnings of ($0.74) per share for the current financial year. For the next year, analysts expect that the company will report earnings of ($0.44) per share. Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that that provide coverage for Evogene.
Shares of Evogene (NASDAQ:EVGN) remained flat at $$4.00 during mid-day trading on Friday. 38 shares of the company’s stock traded hands, compared to its average volume of 28,078. Evogene has a 1 year low of $2.66 and a 1 year high of $5.84. The company has a market capitalization of $103.00, a price-to-earnings ratio of -4.82 and a beta of 1.36.
WARNING: This piece was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another domain, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this piece can be viewed at https://www.americanbankingnews.com/2018/01/14/0-18-eps-expected-for-evogene-ltd-evgn-this-quarter.html.
Evogene Company Profile
Evogene Ltd. (Evogene) is a biotechnology company for the improvement of crop productivity. The Company is engaged in developing seed traits for improved yield and abiotic stress tolerance, seed traits for biotic stress resistance, herbicides and bio-stimulants. The Company operates a seed business under its subsidiary Evofuel Ltd.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.